2026-08-10T05:23:37Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/123262024-11-29T10:38:02Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16978

00925njm 22002777a 4500 dc Trickey, Adam author May, Margaret T author Gill, M John author Grabar, Sophie author Vehreschild, Janne author Wit, Ferdinand W N M author Bonnet, Fabrice author Cavassini, Matthias author Abgrall, Sophie author Berenguer, Juan author Wyen, Christoph author Reiss, Peter author Grabmeier-Pfistershammer, Katharina author Guest, Jodie L author Shepherd, Leah author Teira, Ramon author d'Arminio Monforte, Antonella author Amo, Julia del author Justice, Amy C author Costagliola, Dominique author Sterne, Jonathan A C author 2020 People living with HIV (PLHIV) are more likely than the general population to develop AIDS-defining malignancies (ADMs) and several non-ADMs (NADMs). Information is lacking on survival outcomes and cause-specific mortality after cancer diagnosis among PLHIV. We investigated causes of death within 5 years of cancer diagnosis in PLHIV enrolled in European and North American HIV cohorts starting antiretroviral therapy (ART) 1996-2015, aged ≥16 years, and subsequently diagnosed with cancer. Cancers were grouped: ADMs, viral NADMs and nonviral NADMs. We calculated cause-specific mortality rates (MR) after diagnosis of specific cancers and compared 5-year survival with the UK and France general populations. Among 83,856 PLHIV there were 4,436 cancer diagnoses. Of 603 deaths after ADM diagnosis, 292 (48%) were due to an ADM. There were 467/847 (55%) and 74/189 (39%) deaths that were due to an NADM after nonviral and viral NADM diagnoses, respectively. MR were higher for diagnoses between 1996 and 2005 versus 2006-2015: ADMs 102 (95% CI 92-113) per 1,000 years versus 88 (78-100), viral NADMs 134 (106-169) versus 111 (93-133) and nonviral NADMs 264 (232-300) versus 226 (206-248). Estimated 5-year survival for PLHIV diagnosed with liver (29% [19-39%]), lung (18% [13-23%]) and cervical (75% [63-84%]) cancer was similar to general populations. Survival after Hodgkin's lymphoma diagnosis was lower in PLHIV (75% [67-81%]). Among ART-treated PLHIV diagnosed with cancer, MR and causes of death varied by cancer type, with mortality highest for liver and lung cancers. Deaths within 5 years of NADM diagnoses were more likely to be from cancer than AIDS. Int J Cancer . 2020 Jun 1;146(11):3134-3146. 10.1002/ijc.32895 1097-0215 International journal of cancer 32003460 http://hdl.handle.net/20.500.12105/12326 PLHIV Cohort Mortality Cancer ADM NADM Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies.